<i id='7264938749'><strike id='7264938749'><tt id='7264938749'><pre id='7264938749'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
The cancer drug shortage isn’t new — and neither are the solutions 
Bryan Kohberger seeks indictment dismissal in Idaho college killings case 
Guidelines to prevent youth baseball injuries need more muscle 
The Jan. 6 committee previously recommended Trump be criminally charged. Here's why 
Medical leaders decry Supreme Court decision on affirmative action 
EPA limits use of carcinogenic gas for sterilizing medical devices 
Bright Health sells Medicare Advantage business to Molina 
‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart 
Medicare proposal to cover medical devices draws a mixed reaction 
Interest rates are at a 22 
New air purifier tech could be key to improving indoor air quality 
Medicare coverage of Wegovy, once blocked, now looks possible 
Cancer drug shortages should be causing more outrage 
WuXi out of biotech trade group, U.S. and China relations to blame 
Duchenne breakthrough therapy leaves behind pioneering families 
